Merus NV Business Update Transcript
Hello, and welcome to the Merus investor call. (Operator Instructions)
I'll now turn the conference over to Kathleen Farren, Merus Investor Relations and Corporate Communications. Please go ahead.
Good morning. Thank you for joining our call. The slides we are presenting are also available on our website at www.merus.nl.
On this call, we will also make certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans and events and circumstances, including about finances, intellectual property, protections about Merus's clinical development for 2023 and beyond, and the timing for plans and for meeting clinical and regulatory anticipated milestones related to petosemtamab, zenocutuzumab, and our other by-products candidates.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |